8-K: Omeros Reports Strong Q2 2026 Results, YARTEMLEA Surges

Omeros Corporation announced robust second quarter 2026 financial results, highlighted by a significant increase in YARTEMLEA revenue and improved operational cash flow.

Summary

• Omeros Corporation reported strong financial results for the second quarter ended June 30, 2026.
• YARTEMLEA, a treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), generated $32.2 million in gross revenue, a 190% increase from the previous quarter.
• Net income for the quarter was $13.2 million ($0.18 per share), compared to a net loss of $25.4 million ($0.43 per share) in the same period last year.
• Excluding non-cash gains, non-GAAP adjusted net income was $1.8 million ($0.02 per share), a significant improvement from a non-GAAP adjusted net loss of $17.1 million ($0.24 per share) in the first quarter.
• The company had $132.0 million in cash and short-term investments as of June 30, 2026.
• Net cash provided by operations was $4.1 million for the quarter.
• Omeros repurchased $30.5 million of its 2029 Notes in July 2026, reducing outstanding principal and potential dilution.
• The company also repurchased approximately 0.5 million shares of common stock during the quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong YARTEMLEA revenue growth and improved operational cash flow, despite some regulatory setbacks.

Positives

• YARTEMLEA gross revenues increased by 190% to $32.2 million in Q2 2026 compared to Q1 2026.
• Net income for Q2 2026 was $13.2 million, a substantial turnaround from the prior year's net loss.
• Non-GAAP adjusted net income improved significantly to $1.8 million in Q2 2026 from a net loss in Q1 2026.
• Company-wide net cash provided by operations was $4.1 million in Q2 2026.
• The company successfully repurchased $30.5 million of its 2029 Notes, reducing debt and potential equity dilution.
• The permanent J-code for YARTEMLEA became effective in July 2026, and NTAP status was granted by CMS effective October 1, 2026, expected to support patient access and reimbursement.
• The publication of a peer-reviewed manuscript in Science Translational Medicine on the T-CAT platform highlights its potential.

Negatives

• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application for narsoplimab (YARTEMLEA) in TA-TMA in June 2026.
• The non-cash gain from the mark-to-market adjustment of convertible notes was significantly lower in Q2 2026 ($11.5 million) compared to Q1 2026 ($73.1 million), impacting reported GAAP net income.
• The repurchase of 2029 Notes in July 2026 incurred a total purchase price of $60.2 million, exceeding the principal amount repurchased.

Risks

• Unfavorable or unexpected regulatory conclusions or interpretations related to clinical data for narsoplimab in Europe.
• Inability to respond satisfactorily to information requests during regulatory review for narsoplimab.
• Unanticipated outcomes or requirements of regulatory processes in relevant jurisdictions.
• Challenges in raising additional capital or completing transactions on favorable terms.
• Changes in reimbursement and payment policies by government and commercial payers.
• Intellectual property claims and competitive developments.
• Litigation risks.
• Risks associated with the manufacture or supply of products for clinical trials or commercial sale.

Future Outlook

The company anticipates a broad range of value-driving milestones over the next 18 months from its various programs, including the advancement of its complement, addiction, oncology, and infectious disease platforms. Enrollment is expected to begin in two investigator-sponsored studies for YARTEMLEA by year-end 2026. A Phase 2 clinical program for OMS1029 is being finalized, and a drug development candidate is expected to be selected for the MASP-2 small-molecule inhibitor program. The inpatient clinical trial for OMS527 is expected to begin enrollment by year-end 2026, following an additional nonclinical study. A Phase 1b clinical trial for OMS805 is targeted to begin in late 2027.

Management Comments

• We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEAs commercial launch.
• Equally gratifying are the consistent reports from transplant physicians nationwide describing responses to YARTEMLEA in their adult and pediatric patients, including those who had not responded to prior off-label C5 inhibitor administration.
• YARTEMLEA is saving lives and, with FDA approval, is now broadly accessible in the U.S.
• Substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure.
• We repurchased an additional 489,000 shares of common stock in the open market and reduced the outstanding principal amount of our 2029 convertible notes by 43%, eliminating nearly $9 million in future cash interest payments and approximately 5 million additional shares of potential dilution.
• At the same time, our work with Novo Nordisk on the MASP-3 inhibitor zaltenibart remained on track toward Phase 3 trial initiation, while our complement, addiction, oncology, and infectious disease programs continued advancing.
• Collectively, these programs position Omeros for a broad range of value-driving milestones over the next 18 months.

Industry Context

StockSavvy.ai notes that Omeros' strong Q2 performance, particularly with YARTEMLEA, reflects the growing market for specialized treatments in critical care areas like stem cell transplantation complications. The company's strategic capital allocation, including debt reduction and share repurchases, alongside continued pipeline development, positions it to navigate the competitive biotechnology landscape.

Comparison to Industry Standards

• YARTEMLEA's 190% quarter-over-quarter revenue growth is exceptionally strong, surpassing typical growth rates for newly launched orphan drugs in the biotechnology sector.
• The gross-to-net adjustment of 11.5% for YARTEMLEA is within the expected range for specialty pharmaceuticals, though monitoring this metric will be important as sales scale.
• The company's ability to generate positive operational cash flow ($4.1 million) in Q2 2026, while still investing heavily in R&D, is a positive indicator compared to many early-stage or development-focused biotech firms.
• The successful repurchase of convertible notes demonstrates proactive financial management, a practice seen in mature biotech companies aiming to deleverage and reduce shareholder dilution.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong YARTEMLEA sales growth, successful debt reduction, and share repurchases. However, the negative opinion from EMA on narsoplimab presents a risk.
• Patients: Continued access to YARTEMLEA through expanded access programs in Europe and FDA approval in the U.S. The NTAP designation is expected to improve access.
• Hospitals: Expected to benefit from additional Medicare reimbursement for inpatient cases involving YARTEMLEA due to NTAP status.
• Creditors: Reduced outstanding principal on convertible notes strengthens the company's balance sheet.

Next Steps

• Continue to make YARTEMLEA available to transplant physicians and patients in Europe through the expanded access program.
• Request re-examination of the CHMP negative opinion for narsoplimab in TA-TMA in Europe.
• Enrollment to begin in two investigator-sponsored and Omeros-supported studies for YARTEMLEA by year-end 2026.
• Finalize the initial indication for a Phase 2 clinical program for OMS1029.
• Select a drug development candidate in the MASP-2 small-molecule inhibitor program after completion of an ongoing study.
• Initiate a nonclinical study for OMS527 responsive to FDA requests.
• Begin enrollment in the inpatient clinical trial for OMS527 by year-end 2026.
• Begin IND-enabling studies for OMS805 (OncotoX-AML).

Key Dates

Recommendation

The strong Q2 results, particularly YARTEMLEA's revenue surge and improved non-GAAP profitability, are positive. However, the negative opinion from the EMA regarding narsoplimab in Europe introduces significant uncertainty and risk. While the company is pursuing re-examination, this regulatory hurdle warrants a cautious 'hold' stance until further clarity emerges.

Keywords

YARTEMLEA, TA-TMA, narsoplimab, financial results, biotechnology, convertible notes, MASP-2 inhibitor, clinical trials